Pompe. Lysosomal Disorders. Introduction

Size: px
Start display at page:

Download "Pompe. Lysosomal Disorders. Introduction"

Transcription

1 Introduction disease is an inherited, genetic disorder which results in the lack of an enzyme 'acid alpha-glucosidase. disease is also known as acid maltase deficiency or glycogen storage disease type II. To understand the implications of this it is useful to know a little about this enzymes normal activity. The human body contains many different types of cells. A basic cell has many components as you can see from the diagram below, including the nucleus which contains chromosomes. Within the cell there is a small compartment called the lysosome - this contains all the enzymes the cell needs to manage its recycling of waste products. The enzymes in the lysosome begin the process of breaking down glycogen but in disease this is ineffective. The glycogen accumulates in various types of muscle skeletal (eg limb, body & respiratory muscle), smooth (eg the muscles involved in feeding/swallowing) and cardiac (heart muscle predominantly in children). Inheritance Page 1

2 disease is an inherited genetic disorder described medically as an 'autosomal recessive disease. Each person has 23 pairs of chromosomes which contain genes they receive 1 set from each parent. Genes contain the necessary information to allow our body to be formed and to function. It is estimated that every human being has 8-10 genes that have changes within them (called mutations) however only some can cause disease. disease only produces symptoms when both copies of the gene are affected. This may well have occurred when both parents have 1 copy of the genetic mutation. They are said to be carriers (ie without any evidence of disease) but their offspring may inherit both copies of the faulty gene. There are other possibilities eg if 1 parent has disease and the other either has no mutation or is a carrier. In the former case all the children will be carriers and the latter there is a 50% chance of having an affected child and a 50% chance of a carrier. If you would like further information about the inheritance pattern in your personal circumstances or to know whether it is likely that any other members of your family are affected please discuss this with your physician or specialist nurse. Symptoms The signs and symptoms of disease are directly related to the muscles affected. The disease is progressive in nature, and affects proximal, respiratory and cardiac (infants) muscle. There are currently thought to be 2 main types of disease: Infantile Classic infantile is the most severe end of the spectrum with rapidly progressive cardiomegaly (enlarged heart) hepatomegaly (enlarged liver) weakness and hypotonia ('floppy ). This leads to early death usually in the first year of life Infantile variant has a slower progression and less severe cardiomegaly. It Page 2

3 usually presents during the first year of life Late onset Juvenile pompe presents later than infancy and typically does not include severe cardiomyopathy Adult onset is characterised by a slowly progressive myopathy (muscle weakness) that presents as an adult The severity of the disease and the rate of disease progression varies from person to person. Listed below are the possible symptoms: Page 3

4 Cardiomegaly (enlarged heart) Lysosomal Cardiomyopathy Disorders (weak heart) rarely seen Profound/rapidly progressive - hypotonia (floppy baby) Delayed motor milestones Frequent infections Respiratory insufficiency Cardio-respiratory failure (death) Failure to thrive, feeding difficulties Organomegaly enlarged liver, spleen & tongue Progressive proximal muscle weakness (esp. trunk and lower limbs) Gait abnormalities Muscle pain Difficulty climbing stairs Frequent falls Scapular winging Respiratory failure/insufficiency Morning headache & day time tiredness Orthopnea ( breathing difficulties when laying down) Sleep apnea ( stopping breathing whilst asleep) Exertional shortness of breath Respiratory infections Jaw muscle fatigue & swallowing difficulties At risk of food aspiration Weight stability Osteoporosis/osteopenia Neurological & hearing impairment Osteoporosis/osteopenia Adult onset Infantile onset Treatment Enzyme replacement therapy (ERT) Until recently in the UK treatment for disease was limited to supportive therapy. In April 2006 Genzyme corporation received a product licence for Myozyme. This is the direct replacement of the missing enzyme in disease a treatment known as enzyme Page 4

5 replacement therapy (ERT) This is an intravenous infusion that is give once per fortnight initially in hospital but with the possibility of home infusion if hospital infusions are uneventful. The infusion takes between 4-5 hours to give. This treatment is considered to be an orphan drug" and as such prescribing in England is restricted to NCG centres. In Scotland, Wales and N Ireland, permission must be obtained from the devolved NHS authorities in each region. Side effects are generally mild but may include: Hypersensitivity anaphylactic shock has been reported in a few patients Infusion reactions agitation, tremor, tachycardia (fast heart rate), cyanosis, flushing, hypertension (high blood pressure), pallor, tachypnoea (fast breathing), cough, vomiting, urticaria (rash), fever, rigors (chills), decreased oxygen saturation, hypotension (low blood pressure) & tachycardia (fast heart rate) Note: reactions are more likely if a patient has an acute underlying illness at the time of the Page 5

6 infusion, or if they have reacted to myozyme before. Supportive treatment This will vary considerably depending upon the nature and severity of the symptoms experienced. is a progressive disorder and therefore requires regular assessment to identify which treatments are appropriate. In general these tests should include assessment of cardiac and respiratory function (heart and lung), muscle strength and function, safety when swallowing and diet/weight maintenance. It is likely that people affected by pompe will also need to visit other doctors eg a neurologist, respiratory and/or cardiac physician as well as other healthcare professionals such as the physiotherapist, occupational therapist, speech therapist and dietician. At Addenbrooke s, patients are cared for by an experienced metabolic physician and a specialist nurse who will co-ordinate assessment, treatment and supportive care as necessary, with access to the multi disciplinary team. The input and support of a local physician is also essential. It is considered important for patients to adopt a healthy lifestyle by following dietary advice, exercising within limits and to avoid smoking in order to maintain or improve general health. Page 6

Understanding Late-Onset Pompe Disease

Understanding Late-Onset Pompe Disease Understanding Late-Onset Pompe Disease What Is a Lysosome? Millions of tiny units called cells make up the human body. Each cell has its own job to keep the body running. Within each cell, there are organelles,

More information

Pompe Disease. Family Education Booklet. Division of Pediatric Genetics Metabolism and Genomic Medicine

Pompe Disease. Family Education Booklet. Division of Pediatric Genetics Metabolism and Genomic Medicine Pompe Disease Family Education Booklet Division of Pediatric Genetics Metabolism and Genomic Medicine Table of Contents What is Pompe disease?... 1 How common is Pompe disease?... 1 Basic genetic concepts...

More information

What s New in Newborn Screening?

What s New in Newborn Screening? What s New in Newborn Screening? Funded by: Illinois Department of Public Health Information on Newborn Screening Newborn screening in Illinois is administered by the Illinois Department of Public Health.

More information

Medication Policy Manual. Topic: Lumizyme, alglucosidase alfa Date of Origin: February 17, 2015

Medication Policy Manual. Topic: Lumizyme, alglucosidase alfa Date of Origin: February 17, 2015 Medication Policy Manual Policy No: dru392 Topic: Lumizyme, alglucosidase alfa Date of Origin: February 17, 2015 Committee Approval Date: March 13, 2015 Next Review Date: March 2016 Effective Date: July

More information

DEVELOPING A FOLLOW-UP FRAMEWORK FOR POMPE DISEASE

DEVELOPING A FOLLOW-UP FRAMEWORK FOR POMPE DISEASE DEVELOPING A FOLLOW-UP FRAMEWORK FOR POMPE DISEASE Presenter: Sarah Bradley, MS, CGC Genetic Counselor, NYS Newborn Screening Program Authors: S. Bradley, D. Kronn, B. Vogel, M. Caggana, J. Orsini, K.

More information

There are four different forms of Tarui disease, which are classed by their signs and symptoms and age of presentation.

There are four different forms of Tarui disease, which are classed by their signs and symptoms and age of presentation. Tarui Disease Tarui disease (also known as phosphofructokinase deficiency, or glycogen storage disease type VII) was first described in 1965 by the Japanese physician Seiichiro Tarui and his co-workers.

More information

LSD WORKSHOP WHAT EVERY PEDIATRICIAN SHOULD KNOW. Amal Al Tenaiji Pediatric Metabolic Genetics SKMC Abu Dhabi

LSD WORKSHOP WHAT EVERY PEDIATRICIAN SHOULD KNOW. Amal Al Tenaiji Pediatric Metabolic Genetics SKMC Abu Dhabi LSD WORKSHOP WHAT EVERY PEDIATRICIAN SHOULD KNOW Amal Al Tenaiji Pediatric Metabolic Genetics SKMC Abu Dhabi CASE A 1 month old infant presents with difficulty feeding and respiratory distress. Mom and

More information

What s New in Newborn Screening?

What s New in Newborn Screening? What s New in Newborn Screening? Funded by: Illinois Department of Public Health Information on Newborn Screening Newborn screening in Illinois is mandated and administered by the Illinois Department of

More information

Spinal Muscular Atrophy: Case Study. Spinal muscular atrophy (SMA) is a fairly common genetic disorder, affecting

Spinal Muscular Atrophy: Case Study. Spinal muscular atrophy (SMA) is a fairly common genetic disorder, affecting Spinal Muscular Atrophy: Case Study Spinal muscular atrophy (SMA) is a fairly common genetic disorder, affecting approximately one in 6,000 babies. It is estimated that one in every 40 Americans carries

More information

swine flu vaccination:

swine flu vaccination: swine flu vaccination: what you need to know Flu. Protect yourself and others. Contents What is swine flu?...................3 About the swine flu vaccine...........4 What else do I need to know?.........8

More information

what you need flu. Protect yourself and others.

what you need flu. Protect yourself and others. swine flu vaccination: what you need to know flu. Protect yourself and others. contents What is swine flu?................ 3 About the swine flu vaccine........ 4 What else do I need to know?....... 8

More information

A Lawyer s Perspective on Genetic Screening Performed by Cryobanks

A Lawyer s Perspective on Genetic Screening Performed by Cryobanks A Lawyer s Perspective on Genetic Screening Performed by Cryobanks As a lawyer practicing in the area of sperm bank litigation, I have, unfortunately, represented too many couples that conceived a child

More information

Muscular Dystrophies. Pinki Munot Consultant Paediatric Neurologist Great Ormond Street Hospital Practical Neurology Study days April 2018

Muscular Dystrophies. Pinki Munot Consultant Paediatric Neurologist Great Ormond Street Hospital Practical Neurology Study days April 2018 Muscular Dystrophies Pinki Munot Consultant Paediatric Neurologist Great Ormond Street Hospital Practical Neurology Study days April 2018 Definition and classification Clinical guide to recognize muscular

More information

DNA Day Illinois 2013 Webinar: Newborn Screening and Family Health History. Tuesday, April 16, 2013

DNA Day Illinois 2013 Webinar: Newborn Screening and Family Health History. Tuesday, April 16, 2013 DNA Day Illinois 2013 Webinar: Newborn Screening and Family Health History Tuesday, April 16, 2013 Objectives Recognize the importance & impact of newborn screening Describe the process of newborn screening

More information

Fatty Acid Oxidation Disorders

Fatty Acid Oxidation Disorders Genetic Fact Sheets for Parents Fatty Acid Oxidation Disorders Screening, Technology, and Research in Genetics is a multi-state project to improve information about the financial, ethical, legal, and social

More information

Fatty Acids Synthesis L3

Fatty Acids Synthesis L3 Fatty Acids Synthesis L3 The pathway for fatty acid synthesis occurs in the cytoplasm, whereas, oxidation occurs in the mitochondria. The other major difference is the use of nucleotide co-factors. Oxidation

More information

ANAPHYLAXIS Following Vaccination. A Severe Adverse Event. Developed for the Grampians Infection Control Group (GRICG) Version 2.

ANAPHYLAXIS Following Vaccination. A Severe Adverse Event. Developed for the Grampians Infection Control Group (GRICG) Version 2. ANAPHYLAXIS Following Vaccination A Severe Adverse Event Developed for the Grampians Infection Control Group () Version 2.0:2014 Adverse Event Following Immunisation Adverse event following immunisation

More information

Muscular Dystrophy UK s Adult North Star Network. Care recommendations for adults with Duchenne a consultation

Muscular Dystrophy UK s Adult North Star Network. Care recommendations for adults with Duchenne a consultation Muscular Dystrophy UK s Adult North Star Network Care recommendations for adults with Duchenne a consultation Background: The North Star Network was set up in 2003 to help drive improvements in services

More information

Fatty Acid Oxidation Disorders

Fatty Acid Oxidation Disorders Genetic Fact Sheets for Parents Fatty Acid Oxidation Disorders Screening, Technology, and Research in Genetics is a multi-state project to improve information about the financial, ethical, legal, and social

More information

INTRODUCTION. 1.

INTRODUCTION. 1. KRABBE DISEASE INTRODUCTION Krabbe disease is a genetic defect that affects the nervous system. It is caused by the shortage (deficiency) of an enzyme called galactosylceramidase. This enzyme deficiency

More information

The Changing Face of Infantile Pompe Disease: A Report of Five Patients from the UAE

The Changing Face of Infantile Pompe Disease: A Report of Five Patients from the UAE JIMD Reports DOI 10.1007/8904_2012_148 RESEARCH REPORT The Changing Face of Infantile Pompe Disease: A Report of Five Patients from the UAE Waseem Fathalla Elamin Ahmed Received: 02 July 2011 /Revised:

More information

Clinical Summaries. CLN1 Disease, infantile onset and others

Clinical Summaries. CLN1 Disease, infantile onset and others Clinical Summaries CLN1 Disease, infantile onset and others The gene called CLN1 lies on chromosome 1. CLN1 disease is inherited as an autosomal recessive disorder, which means that both chromosomes carry

More information

THE FOUNDATION OF MORQUIO A MANAGEMENT

THE FOUNDATION OF MORQUIO A MANAGEMENT VIMIZIM THE FOUNDATION OF MORQUIO A MANAGEMENT A comprehensive guide to help you manage your condition Life-threatening allergic reactions, known as anaphylaxis, can occur during VIMIZIM infusions. Typical

More information

Anaphylaxis: Treatment in the Community

Anaphylaxis: Treatment in the Community : Treatment in the Community is likely if a patient who, within minutes of exposure to a trigger (allergen), develops a sudden illness with rapidly progressing skin changes and life-threatening airway

More information

GUIDELINES FOR WEIGHT-BASED DOSING AND INFUSION

GUIDELINES FOR WEIGHT-BASED DOSING AND INFUSION GUIDELINES FOR WEIGHT-BASED DOSING AND INFUSION Includes Example dose calculation wheel Preparation and administration information for healthcare professionals Please see enclosed full Prescribing Information,

More information

THE FOUNDATION OF MORQUIO A MANAGEMENT

THE FOUNDATION OF MORQUIO A MANAGEMENT VIMIZIM (elosulfase alfa) THE FOUNDATION OF MORQUIO A MANAGEMENT A comprehensive guide to help you manage your condition Life-threatening allergic reactions, known as anaphylaxis, can occur during VIMIZIM

More information

Myotubular (centronuclear) myopathy

Myotubular (centronuclear) myopathy Myotubular (centronuclear) myopathy Myotubular, or centronuclear, myopathy falls under the umbrella of congenital myopathies. It is characterised by a specific pattern in the muscle tissue when viewed

More information

B1 Question 1 Foundation

B1 Question 1 Foundation B1 Question 1 Foundation The nucleus controls the activities of a cell. The instructions for how an organism develops i.e. the genes are found in the nuclei of its cells B1 Question 2 Foundation The genes

More information

+ Color Change - + Hearing Loss - + Apnea - + Enuresis (urine - + Tremors - + Rash -

+ Color Change - + Hearing Loss - + Apnea - + Enuresis (urine - + Tremors - + Rash - Review of Systems: 0-1 year old Constitution neg Eyes neg GI neg Neurological neg + Activity Change - + Eye Discharge - + Reflux - + Facial Asymmetry - + Appetite Change - + Eye Redness - + Vomiting -

More information

Robotic-assisted lingual tonsillectomy for sleep apnoea

Robotic-assisted lingual tonsillectomy for sleep apnoea Robotic-assisted lingual tonsillectomy for sleep apnoea You have been given this leaflet because you have been referred for a robotic-assisted lingual tonsillectomy for sleep apnoea. This leaflet offers

More information

Multiple System Atrophy

Multiple System Atrophy Multiple System Atrophy This document has been prepared to help you become more informed about Multiple System Atrophy. It is designed to answer questions about the condition and includes suggestions on

More information

Autoimmune lymphoproliferative syndrome (ALPS)

Autoimmune lymphoproliferative syndrome (ALPS) ALPS Autoimmune lymphoproliferative syndrome (ALPS) Information for families hello@piduk.org 0800 987 8986 www.piduk.org About this leaflet This leaflet is designed to help answer the questions families

More information

Anaphylaxis: treatment in the community

Anaphylaxis: treatment in the community : treatment in the community Item Type Guideline Authors Health Service Executive Citation Health Service Executive. : treatment in the community. Dublin: Health Service Executive;. 5p. Publisher Health

More information

Package leaflet: Information for the user. Myozyme 50 mg powder for concentrate for solution for infusion Alglucosidase alfa

Package leaflet: Information for the user. Myozyme 50 mg powder for concentrate for solution for infusion Alglucosidase alfa Package leaflet: Information for the user Myozyme 50 mg powder for concentrate for solution for infusion Alglucosidase alfa Read all of this leaflet carefully before you start using this medicine because

More information

Package leaflet: Information for the user. Elaprase 2 mg/ml concentrate for solution for infusion idursulfase

Package leaflet: Information for the user. Elaprase 2 mg/ml concentrate for solution for infusion idursulfase Package leaflet: Information for the user Elaprase 2 mg/ml concentrate for solution for infusion idursulfase This medicine is subject to additional monitoring. This will allow quick identification of new

More information

Opinion 9 January 2013

Opinion 9 January 2013 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 9 January 2013 The draft opinion adopted by the Transparency Committee on 7 November 2012 was the subject of a hearing

More information

Nemaline (rod) myopathies

Nemaline (rod) myopathies Nemaline (rod) myopathies Nemaline, or rod, myopathies are a group of conditions which fall under the umbrella of congenital myopathies. They are characterised by rod-like structures in the muscle cells,

More information

PROCEDURE FOR MANAGING AN ANAPHYLACTIC EMERGENCY

PROCEDURE FOR MANAGING AN ANAPHYLACTIC EMERGENCY MULTIDISCIPLINARY PROCEDURE PROCEDURE FOR MANAGING AN ANAPHYLACTIC EMERGENCY First Issued June 2011 Issue Version Four Purpose of Issue/Description of Change Planned Review Date To promote safe and consistent

More information

1/28/2019. OSF HealthCare INI Care Center Team. Neuromuscular Disease: Muscular Dystrophy. OSF HealthCare INI Care Center Team: Who are we?

1/28/2019. OSF HealthCare INI Care Center Team. Neuromuscular Disease: Muscular Dystrophy. OSF HealthCare INI Care Center Team: Who are we? Neuromuscular Disease: Muscular Dystrophy Muscular Dystrophy Association (MDA) and OSF HealthCare Illinois Neurological Institute (INI) Care Center Team The Neuromuscular clinic is a designated MDA Care

More information

This leaflet answers some common questions about HERCEPTIN SC. It does not contain all the available information.

This leaflet answers some common questions about HERCEPTIN SC. It does not contain all the available information. Consumer Medicine Information HERCEPTIN SC Trastuzumab 600 mg/5 ml solution for subcutaneous injection What is in this leaflet This leaflet answers some common questions about HERCEPTIN SC. It does not

More information

This fact sheet describes the condition Fragile X and includes a discussion of the symptoms, causes and available testing.

This fact sheet describes the condition Fragile X and includes a discussion of the symptoms, causes and available testing. 11111 Fact Sheet 54 FRAGILE X SYNDROME This fact sheet describes the condition Fragile X and includes a discussion of the symptoms, causes and available testing. In summary Fragile X is a condition caused

More information

ANAPHYLAXIS. Following Vaccination of Adults. A Severe Adverse Event

ANAPHYLAXIS. Following Vaccination of Adults. A Severe Adverse Event ANAPHYLAXIS Following Vaccination of Adults A Severe Adverse Event Developed for the Grampians Infection Control Group () Version 3.0:2018 Target audience This information package is for nurse immunisers

More information

Newborn screening for congenital metabolic diseases Optional out-of-pocket tests Information Sheet

Newborn screening for congenital metabolic diseases Optional out-of-pocket tests Information Sheet Newborn screening for congenital metabolic diseases Optional out-of-pocket tests Information Sheet Website:www.tipn.org.tw Telephone:(02)85962050 Ext. 401-403 Service line:(02)85962065 Fax:(02)85962067

More information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. (em-plis-city)

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. (em-plis-city) READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr Empliciti TM (em-plis-city) (elotuzumab 300 & 400 mg powder for concentrate for solution for infusion) Read this

More information

Package leaflet: Information for patient

Package leaflet: Information for patient Package leaflet: Information for patient Apresoline Ampoules 20mg Powder for concentrate for solution for injection or infusion Hydralazine hydrochloride Read all of this leaflet carefully before you start

More information

Treatment Strategies for a Complex

Treatment Strategies for a Complex Treatment Strategies for a Complex Neuromuscular Disease: The Pompe Story Barry J. Byrne, MD, PhD Pediatrics and Powell Gene Therapy Center University of Florida, College of Medicine 2 4 Initial Presentation

More information

Inheritance of Gaucher Disease

Inheritance of Gaucher Disease Sarah Mother of a child with Gaucher Working toward a healthy future Helping her son achieve his own dreams, too Straight Talk For Patients and Families Inheritance of Gaucher Disease Genzyme Corporation

More information

Product Information BROWN SNAKE ANTIVENOM AUST R 74897

Product Information BROWN SNAKE ANTIVENOM AUST R 74897 Product Information APPROVED NAME BROWN SNAKE ANTIVENOM AUST R 74897 DESCRIPTION BROWN SNAKE ANTIVENOM is prepared from the plasma of horses immunised with the venom of the brown snake (Pseudonaja textilis).

More information

OSA in children. About this information. What is obstructive sleep apnoea (OSA)?

OSA in children. About this information. What is obstructive sleep apnoea (OSA)? About this information This information explains all about sleep-related breathing problems in children, focusing on the condition obstructive sleep apnoea (OSA). It tells you what the risk factors are

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Myozyme 50 mg powder for concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial contains

More information

Medical Specialists. SPECIALTY (type in contact name and phone number)

Medical Specialists. SPECIALTY (type in contact name and phone number) Medical Specialists SPECIALTY (type in contact name and phone number) Cardiothoracic Surgeon or Cardiovascular Surgeon Pediatric Cardiologist DESCRIPTION A physician specializing in surgical procedures

More information

BEVACIZUMAB (AVASTIN ) & Paclitaxel PROTOCOL

BEVACIZUMAB (AVASTIN ) & Paclitaxel PROTOCOL Bevacizumab (Avastin ) & Paclitaxel The treatment of Advanced Breast Cancer DRUG ADMINISTRATION Da Drug Daily Dose Route Diluent & Rate y 250mls Sodium Day 1,15 Bevacizumab 10 mg/kg Infusion Chloride 0.9%*

More information

Amino Acid Disorders. What is ASAL deficiency? Genetic Fact Sheets for Parents

Amino Acid Disorders. What is ASAL deficiency? Genetic Fact Sheets for Parents Genetic Fact Sheets for Parents Amino Acid Disorders Screening, Technology, and Research in Genetics is a multi-state project to improve information about the financial, ethical, legal, and social issues

More information

Information leaflet for patients and families. Huntington Disease (HD)

Information leaflet for patients and families. Huntington Disease (HD) Information leaflet for patients and families Huntington Disease (HD) Introduction Huntington disease, or Huntington Chorea, (HD) is a slowly progressive disorder of the brain in adults. HD is an inherited

More information

Inborn Error Of Metabolism :

Inborn Error Of Metabolism : Inborn Error Of Metabolism : Inborn Error Of Metabolism inborn error of metabolism are a large group of hereditary biochemical diseases in which specific gene mutation cause abnormal or missing proteins

More information

Neonatal and infant health. What to look out for in babies up to 6 months old. Anoo Jain Neonatal Consultant

Neonatal and infant health. What to look out for in babies up to 6 months old. Anoo Jain Neonatal Consultant Neonatal and infant health What to look out for in babies up to 6 months old Anoo Jain Neonatal Consultant CONTEXT Obstetrics Local & Regional Maternal Medicine Fetal Medicine NICU Genetics/ENT/Gynae Content

More information

swine flu vaccination:

swine flu vaccination: swine flu vaccination: information for parents of children over six months and under five years old Flu. Protect yourself and others. Contents About this leaflet......................... 3 What is swine

More information

Summary of the risk management plan (RMP) for Ristempa (pegfilgrastim)

Summary of the risk management plan (RMP) for Ristempa (pegfilgrastim) EMA/183255/2015 Summary of the risk management plan (RMP) for Ristempa (pegfilgrastim) This is a summary of the risk management plan (RMP) for Ristempa, which details the measures to be taken in order

More information

Medical Advisory Council: Verified

Medical Advisory Council: Verified What is White Sutton Syndrome? White Sutton Syndrome (WHSUS) is a condition characterized by autism and developmental delay and/or intellectual disability, as well as a characteristic facial profile. Children

More information

What You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide

What You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide For Patients What You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide Patients: Your doctor or nurse will go over this patient guide with you. It is important to ask any questions

More information

INVESTIGATION OF ADVERSE TRANSFUSION REACTIONS TABLE OF RECOMMENDED TESTS. Type of Reaction Presentation Recommended Tests Follow-up Tests

INVESTIGATION OF ADVERSE TRANSFUSION REACTIONS TABLE OF RECOMMENDED TESTS. Type of Reaction Presentation Recommended Tests Follow-up Tests Minor Allergic (Urticarial) Urticaria, pruritis, flushing, rash If skin reaction only and mild hives/ rash

More information

All about the adult cystic fibrosis service

All about the adult cystic fibrosis service All about the adult cystic fibrosis service All about the adult cystic fibrosis service Lay Introduction to Cystic Fibrosis Service Specification Since April 2013, NHS England has taken on direct responsibility

More information

Cost-effectiveness of sebelipase alfa (Kanuma ) for the treatment of lysosomal acid lipase (LAL) deficiency infantile paediatric adult

Cost-effectiveness of sebelipase alfa (Kanuma ) for the treatment of lysosomal acid lipase (LAL) deficiency  infantile paediatric adult Cost-effectiveness of sebelipase alfa (Kanuma ) for the treatment of lysosomal acid lipase (LAL) deficiency The NCPE has issued a recommendation regarding the cost-effectiveness of sebelipase alfa (Kanuma

More information

Cardiac Considerations and Care in Children with Neuromuscular Disorders

Cardiac Considerations and Care in Children with Neuromuscular Disorders Cardiac Considerations and Care in Children with Neuromuscular Disorders - importance of early and ongoing treatment, management and available able medications. Dr Bo Remenyi Department of Cardiology The

More information

MabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection

MabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults

More information

Management of an immediate adverse event following immunisation

Management of an immediate adverse event following immunisation Management of an immediate adverse event following immunisation The vaccinated person should remain under observation for a short interval to ensure that they do not experience an immediate adverse event.

More information

Database of Adverse Event Notifications - medicines

Database of Adverse Event Notifications - medicines Database of Adverse Event Notifications - medicines You searched for the following 3 medicines between 01/01/2017 01/01/2018: Ferinject 100mg/2mL (Ferric carboxymaltose) Ferinject 500mg/10mL (Ferric carboxymaltose)

More information

HYPERTROPHIC CARDIOMYOPATHY

HYPERTROPHIC CARDIOMYOPATHY HYPERTROPHIC CARDIOMYOPATHY Most often diagnosed during infancy or adolescence, hypertrophic cardiomyopathy (HCM) is the second most common form of heart muscle disease, is usually genetically transmitted,

More information

Your Mepact (mifamurtide) treatment and what to expect from it. Information for patients who have been prescribed mifamurtide for osteosarcoma.

Your Mepact (mifamurtide) treatment and what to expect from it. Information for patients who have been prescribed mifamurtide for osteosarcoma. Your Mepact (mifamurtide) treatment and what to expect from it. Information for patients who have been prescribed mifamurtide for osteosarcoma. Introduction to Mepact (mifamurtide) Mepact, also known as

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: nusinersen_spinraza 03/2017 10/2017 10/2018 10/2017 Description of Procedure or Service Spinal muscular atrophy

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Atezolizumab PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:

More information

Wilson's Disease. A Guide. An explanation of what Wilson's disease is, symptoms, diagnosis and treatment

Wilson's Disease. A Guide. An explanation of what Wilson's disease is, symptoms, diagnosis and treatment A Guide An explanation of what Wilson's disease is, symptoms, diagnosis and treatment What is Wilson's disease?... 4 Why does the body contain copper?... 4 What causes Wilson s disease?... 5 Are males

More information

Sleep History Questionnaire

Sleep History Questionnaire Sleep History Questionnaire Name: DOB: Phone: Date of Consultation: Consultation is requested by: Primary care provider: _ Preferred pharmacy: Chief complaint: Please tell us why you are here: How long

More information

Hereditary Haemochromatosis For GPs

Hereditary Haemochromatosis For GPs Hereditary Haemochromatosis For GPs What is Hereditary Haemochromatosis? Hereditary Haemochromatosis () is a common autosomal recessive disease resulting in excessive absorption of dietary iron from the

More information

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE SHARED CARE GUIDELINE FOR THE USE OF RILUZOLE IN THE TREATMENT OF MOTOR NEURONE DISEASE

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE SHARED CARE GUIDELINE FOR THE USE OF RILUZOLE IN THE TREATMENT OF MOTOR NEURONE DISEASE BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE SHARED CARE GUIDELINE FOR THE USE OF RILUZOLE IN THE TREATMENT OF MOTOR NEURONE DISEASE PATIENT S NAME: PATIENT S ADDRESS: HOSPITAL NAME AND NUMBER /

More information

Friday, January 4. Bell Work:

Friday, January 4. Bell Work: Friday, January 4 Bell Work: Red green colorblindness is an X linked trait and is recessive. A male who is normal marries a woman who is a carrier, what is the phenotypic ratio of their offspring? 1 Genetic

More information

PKU TEMPLE. Tools Enabling Metabolic Parents LEarning ADAPTED AND ENDORSED BY ASIEM FOR USE IN ANZ DESIGNED AND ADAPTED BY THE DIETITIANS GROUP

PKU TEMPLE. Tools Enabling Metabolic Parents LEarning ADAPTED AND ENDORSED BY ASIEM FOR USE IN ANZ DESIGNED AND ADAPTED BY THE DIETITIANS GROUP TEMPLE Tools Enabling Metabolic Parents LEarning ADAPTED AND ENDORSED BY ASIEM FOR USE IN ANZ Australasian Society for Inborn Errors of Metabolism DESIGNED AND ADAPTED BY THE DIETITIANS GROUP PKU British

More information

TEMPLE. Tools Enabling Metabolic Parents LEarning ADAPTED BY THE DIETITIANS GROUP. British Inherited Metabolic Diseases Group

TEMPLE. Tools Enabling Metabolic Parents LEarning ADAPTED BY THE DIETITIANS GROUP. British Inherited Metabolic Diseases Group TEMPLE Tools Enabling Metabolic Parents LEarning ADAPTED BY THE DIETITIANS GROUP British Inherited Metabolic Diseases Group BASED ON THE ORIGINAL TEMPLE WRITTEN BY KOLKER AND BURGARD GA1 Information for

More information

Congenital myasthenic syndromes (CMS)

Congenital myasthenic syndromes (CMS) Congenital myasthenic syndromes (CMS) This fact sheet is for children and adults diagnosed with congenital myasthenic syndrome. It s a complex subject, so information has been adapted to suit all audiences.

More information

Infantile-onset glycogen storage disease type II

Infantile-onset glycogen storage disease type II Case Report 379 Infantile-Onset Glycogen Storage Disease Type II (Pompe Disease): Report of a Case with Genetic Diagnosis and Pathological Findings Yao-Tun Teng, MD; Wen-Jen Su, MD; Jia-Wei Hou 1, MD,

More information

Package leaflet: Information for the user

Package leaflet: Information for the user CSL Behring Package leaflet: Information for the user Alburex 5, 50 g/l, solution for infusion & Alburex 20, 200 g/l, solution for infusion Human albumin Read all of this leaflet carefully before you are

More information

Newborn Screening for Lysosomal Storage Diseases in Missouri. Outline

Newborn Screening for Lysosomal Storage Diseases in Missouri. Outline Newborn Screening for Lysosomal Storage Diseases in Missouri Dr. Kathy Grange Division of Genetics and Genomic Medicine Department of Pediatrics Washington University Outline Brief overview of clinical

More information

PATIENT INFORMATION LEAFLET AMLOC RANGE

PATIENT INFORMATION LEAFLET AMLOC RANGE SCHEDULING STATUS: S3 PROPRIETARY NAME AND DOSAGE FORM: AMLOC 5 mg tablets AMLOC 10 mg tablet Read all of this leaflet carefully before you start taking AMLOC. Keep this leaflet. You may need to read it

More information

An information leaflet for patients and families. Von Hippel- Lindau Disease

An information leaflet for patients and families. Von Hippel- Lindau Disease An information leaflet for patients and families Von Hippel- Lindau Disease What is Von Hippel-Lindau disease? Von Hippel-Lindau (VHL) disease is a rare inherited disorder caused by a genetic alteration

More information

How are unresolved Myasthenia Gravis symptoms disrupting your day? Talk to your doctor about your symptoms

How are unresolved Myasthenia Gravis symptoms disrupting your day? Talk to your doctor about your symptoms How are unresolved Myasthenia Gravis symptoms disrupting your day? Talk to your doctor about your symptoms Recognize the symptoms of your generalized Myasthenia Gravis (gmg) Anti-acetylcholine receptor

More information

Multiple Sclerosis. What is multiple sclerosis? What is the cause? What are the symptoms?

Multiple Sclerosis. What is multiple sclerosis? What is the cause? What are the symptoms? What is multiple sclerosis? Multiple Sclerosis Multiple sclerosis (MS) is a disease of the central nervous system (the brain and spinal cord). Many people with multiple sclerosis are only mildly affected

More information

About general anaesthesia Day Surgery Unit Patient Information Leaflet

About general anaesthesia Day Surgery Unit Patient Information Leaflet About general anaesthesia Day Surgery Unit Patient Information Leaflet Originator: Nahla Farid - Consultant Anaesthetist Date: November 2011 Version: 1 Date for Review: November 2014 DGOH Ref No: DGOH/PIL/00560

More information

Duct Dependant Congenital Heart Disease

Duct Dependant Congenital Heart Disease Children s Acute Transport Service Clinical Guidelines Duct Dependant Congenital Heart Disease This guideline has been agreed by both NTS & CATS Document Control Information Author CATS/NTS Author Position

More information

Haemophagocytic lymphohistiocytosis (HLH)

Haemophagocytic lymphohistiocytosis (HLH) HLH Haemophagocytic lymphohistiocytosis (HLH) Information for families hello@piduk.org 0800 987 8986 www.piduk.org About this leaflet This booklet has been produced jointly between PID UK, Great Ormond

More information

*Monitor for significant side effects, especially symptoms of neurological or cardiovascular events.

*Monitor for significant side effects, especially symptoms of neurological or cardiovascular events. Assessment Prior to administration: Obtain complete health history including allergies, drug history, and possible drug reactions Assess reason for drug administration such as presence/history of anemia

More information

PRODUCT MONOGRAPH. Pr MYOZYME. alglucosidase alfa (Recombinant human acid alpha-glucosidase) Lyophilized Powder 50 mg vial. Enzyme Replacement Therapy

PRODUCT MONOGRAPH. Pr MYOZYME. alglucosidase alfa (Recombinant human acid alpha-glucosidase) Lyophilized Powder 50 mg vial. Enzyme Replacement Therapy PRODUCT MONOGRAPH Pr MYOZYME alglucosidase alfa (Recombinant human acid alpha-glucosidase) Lyophilized Powder 50 mg vial Enzyme Replacement Therapy Sanofi Genzyme, a division of Sanofi-Aventis Canada Inc.

More information

Duct Dependant Congenital Heart Disease

Duct Dependant Congenital Heart Disease Children s Acute Transport Service Clinical Guidelines Duct Dependant Congenital Heart Disease Document Control Information Author CATS/NTS Author Position CC Transport Services Document Owner E. Polke

More information

Organic Acid Disorders

Organic Acid Disorders Genetic Fact Sheets for Parents Organic Acid Disorders Screening, Technology, and Research in Genetics is a multi-state project to improve information about the financial, ethical, legal, and social issues

More information

Cardiovascular Genetics Clinic Arrhythmia Questionnaire

Cardiovascular Genetics Clinic Arrhythmia Questionnaire Name: Address: Home Phone: Cell Phone: Email Address: Date of Birth: Primary Care Physician: Why have you been referred for a Cardiovascular Genetics Appointment? Have you had a genetics evaluation? If

More information

Disclosures. This speaker has indicated there are no relevant financial relationships to be disclosed.

Disclosures. This speaker has indicated there are no relevant financial relationships to be disclosed. Disclosures This speaker has indicated there are no relevant financial relationships to be disclosed. Parkinson s Disease, Huntington s Disease and ALS: A brief overview of three diagnoses Leo G. Rafail,

More information

Acute kidney injury. Information for patients Sheffield Teaching Hospitals

Acute kidney injury. Information for patients Sheffield Teaching Hospitals Acute kidney injury Information for patients Sheffield Teaching Hospitals page 2 of 12 Acute kidney injury You have been given this leaflet because you have had an episode of acute kidney injury (AKI).

More information

Risks of Smoking in Pregnancy

Risks of Smoking in Pregnancy Information leaflet on Risks of Smoking in Pregnancy Routine Antenatal Carbon Monoxide Recording 1 Risks of Smoking during Pregnancy Smoking is the single greatest cause of ill health and premature death

More information

Guide to Understanding Metachromatic Leukodystrophy

Guide to Understanding Metachromatic Leukodystrophy Guide to Understanding Metachromatic Leukodystrophy 0845 389 9901 mps@mpssociety.org.uk www.mpssociety.org.uk Contents What is MLD? What causes MLD? Are there different forms of MLD? How common is MLD?

More information

Glycogen Storage Disease Type III also known as Cori or Forbe s Disease/Debrancher Enzyme Deficiency

Glycogen Storage Disease Type III also known as Cori or Forbe s Disease/Debrancher Enzyme Deficiency Glycogen Storage Disease Type III also known as Cori or Forbe s Disease/Debrancher Enzyme Deficiency What is GSDIII? Glycogen Storage Disease type 3 is an inherited condition caused by a defect in a gene

More information